---
schema_version: "secwatch.filing_event.v1"
accession: "0000917520-26-000008"
form_type: "8-K"
ticker: "IART"
cik: "0000917520"
company_name: "INTEGRA LIFESCIENCES HOLDINGS CORP"
filed_at: "2026-02-26T23:59:59+00:00"
generated_at: "2026-05-16T00:00:04.696428+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Integra Q4 rev -1.7% organic; FY GAAP loss $6.74/sh on $511M goodwill impairment; 2026 adj EPS guidance $2.30-$2.40

## Summary
- Q4 2025 revenues $434.9M (-1.7% reported, -2.5% organic YoY); GAAP EPS $(0.02) vs $0.25; adj EPS $0.83 vs $0.97.
- FY 2025 revenues $1,635.2M (+1.5% reported, -0.7% organic); GAAP net loss $516.5M ($6.74/sh) includes $511M goodwill impairment.
- Codman Specialty Surgical segment rev $323.3M (+2.7% reported); Tissue Technologies rev $111.6M (-12.8% reported) driven by MediHoney remediation and Integra Skin comp.
- 2026 guidance: revenues $1,662-$1,702M (0.8%-3.3% organic growth); adj EPS $2.30-$2.40; Q1 2026 rev $375-$390M.
- Transformation plan simplifies operating model targeting $25-$30M savings in 2026; net debt $1.6B, leverage 4.5x, liquidity $516M.

## SEC filing metadata
- accession: 0000917520-26-000008
- form_type: 8-K
- ticker: IART
- cik: 0000917520
- company_name: INTEGRA LIFESCIENCES HOLDINGS CORP
- filed_at: 2026-02-26T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/917520/000091752026000008/0000917520-26-000008-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/917520/000091752026000008/iart-20260226.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000917520-26-000008
- JSON: https://secwatch.observer/filing/0000917520-26-000008.json
- Plain text: https://secwatch.observer/filing/0000917520-26-000008.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.